title: Polymorphisms of HLA-DM on Treatment Response to Interferon/Ribavirin in Patients with Chronic Hepatitis C Virus Type 1 Infection.
abstract: HLA-DMgene, which is related to antigen processing and presentation and located in the non-classical class-II region of human leukocyte antigen (HLA) region, may play a crucial role in chronic hepatitis C virus (HCV) infection treatment outcomes. The study was conducted to evaluate the role of the variant of several single nucleotide polymorphisms (SNPs) inHLA-DMgene in HCV treatment outcomes.
  
  
  
  We genotyped four SNPs from the candidate genes (HLA-DMAandDMB) in 336 patients who were treated with pegylated interferon-alpha and ribavirin (PEG IFN-α/RBV). Multivariate analysis of factors predicting sustained virological response (SVR) was conducted.
  
  
  
  HLA-DMArs1063478 andDMBrs23544 were independent factors of HCV treatment outcomes in Chinese Han population. Individuals who carried favorable genotypes of rs1063478TT and rs23544GG were more likely to achieve SVR {Dominant model: odds ratio (OR) = 2.05, 95% confidence interval (CI) = 1.24-3.41; OR = 2.04, 95% CI =1.23-3.35, respectively}. Rs23544, rs1063478, baseline glucose, baseline platelet and T4 level were independent predictors of SVR. The area under the receiver operating characteristic (ROC) curve (AUC) was 0.740.
  
  
  
  The genetic variation of rs1063478 and rs23544 are associated with the treatment outcomes in the Chinese Han population.
authors: Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, China. chb2180@126.com.
authors: Hongbo
authors: H
authors: Chen
authors: Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China. yinanyao1130@163.com.
authors: Yinan
authors: Y
authors: Yao
authors: Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, China. yifanwang333@163.com.
authors: Yifan
authors: Y
authors: Wang
authors: Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, China. huazhou4456@163.com.
authors: Hua
authors: H
authors: Zhou
authors: Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, China. xutianq@163.com.
authors: Tianxiang
authors: T
authors: Xu
authors: Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, China. xyxJ6300@sina.com.
authors: Jing
authors: J
authors: Liu
authors: Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, China. guochengwang4456@163.com.
authors: Guocheng
authors: G
authors: Wang
authors: Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, China. yongfengzhang666@163.com.
authors: Yongfeng
authors: Y
authors: Zhang
authors: Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, China. xiangchen322@163.com.
authors: Xiang
authors: X
authors: Chen
authors: Department of Infectious Disease, the Jurong People's Hospital, Jurong 212400, China. lin553210@163.com.
authors: Qingwei
authors: Q
authors: Liu
authors: Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China. huangpeng@njmu.edu.cn.
authors: Peng
authors: P
authors: Huang
authors: Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, China. rongbinyu@njmu.edu.cn.
authors: Rongbin
authors: R
authors: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000276:immunology / Q000627:therapeutic use*; D044466:Asian People / Q000235:genetics*; D002681:China; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D006681:HLA-D Antigens / Q000235:genetics* / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D006681:HLA-D Antigens; C084245:HLA-DM antigens; D016898:Interferon-alpha; D012254:Ribavirin
keywords: HLA-DM gene; genetic polymorphism; hepatitis C; treatment outcome